NTII Neurobiological Technologies (MM)

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII), today announced it has received a quarterly royalty payment of approximately $2.0 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners. About Neurobiological Technologies, Inc. Neurobiological Technologies, Inc., (NASDAQ:NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Matthew M. Loar, Chief Financial Officer of Neurobiological Technologies, Inc., +1-510-595-6000 Web site: http://www.ntii.com/

Copyright